BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,500 shares of its common stock to nine newly-hired employees, with a grant date of January 18, 2024.

Aadi Bioscience, Inc. announced poster presentations at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA.

Iovance Biotherapeutics, Inc. announced that on January 18, 2024, the Company approved the grant of inducement stock options covering an aggregate of 51,375 shares of Iovance’s common stock to six new non-executive employees.

Tampa General Hospital announced that the TGH Cancer Institute recently completed Florida’s first successful infusion of Hemgenix, a gene therapy option for patients with severe hemophilia B — a rare bleeding disorder characterized by failure of the blood to clot properly.

The presentation will focus on the use of mRNA in Liquid Biopsies as a platform for precision diagnostics

Johnson & Johnson announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application for BALVERSA® for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible fibroblast growth factor receptor 3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.

Ultragenyx Pharmaceutical Inc. reported the grant of 12,130 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company.

Acadia Pharmaceuticals Inc. announced that on January 9, 2024, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 39,169 shares of common stock and 13,895 restricted stock units to eleven new employees under Acadia’s 2023 Inducement Plan.

Apollomics Inc. announced that on January 16, 2024, it received a notification from The Nasdaq Stock Market LLC stating that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550, because the closing bid price of the Company’s Class A ordinary shares, par value $0.0001 per share, was below $1.00 per share for 30 consecutive business days.